Business Wire

PUMA

16.5.2023 15:41:29 CEST | Business Wire | Press release

Share
PUMA x Modibodi® Making It More Comfortable to Bleed, Whatever Uniform You Play In

Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005712/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA. (Photo: Business Wire)

Ever worn white or tight sports uniforms that made you feel uncomfortable about leaking when playing on your period? Or felt exposed in sportswear that left the wings and strings of your disposables on display?

From archaic sports codes to national team uniform fines, athletes are often told to keep playing on their period, when what they’re told to wear makes it extremely uncomfortable and anxiety-inducing.

But that’s about to change. Enter PUMA x Modibodi active period underwear. The new PUMA x Modibodi active period underwear is in league of its own – made for maximum protection and performance on and off the court, field or gym floor. The collection combines soft, breathable fabrics that stretch and move with your body with Modibodi’s concealed absorbent lining, proven to keep you free from leaks, sweat and discharge.

Modibodi Ambassador and Brisbane City FC Captain, Jamilla Riley, says: “As someone who menstruates and plays soccer in a white uniform, I can attest to the discomfort and anxiety that combination can create, particularly when you are young. You spend your time shamed by the fear of leaks, and it can take all your mental strength to refocus on the game at hand. That’s why I’m such an advocate of the new PUMA x Modibodi active period undies. The designs not only bring some much-needed innovation to the sportswear market, but they also help support your menstruating body so you can play without fear of leaking and kick some goals. Who knew playing on your period could be this comfy It’s liberating!”

Modibodi Design and Innovation Director, Charissa Lanham says: “We wanted to destigmatise the challenges of menstruating whilst competing and show athletes a new world in which they can feel confident and supported to play while they bleed. We worked with PUMA to design a range of active period underwear that utilises Modibodi’s world-first patented technology which includes a leak-proof barrier layer for secure protection; meaning athletes can focus on their game, not their period.”

A workout staple, the PUMA x Modibodi collection absorbs fast and offers peace of mind on the pitch by replacing the need for disposable pads, liners and tampons as you play. The super slim, absorbent black lining is designed to help prevent leaks and unwanted stains. Featuring 3 layers of built-in technology that can hold up to 15ml (or 2-3 tampons) without staining your activewear or sports uniform.

To ensure comfort, each design is crafted from 82% recycled material, includes a wider logo waist band for security whilst playing and an aerated mesh side panel to maximise airflow. Modibodi’s proprietary Modifier Technology™ then works to wick moisture and sweat, locking away fluid and odour to keep you feeling fresh and dry.

Available in a two-colour ways Black/Platinum Grey and Black/Green, the collection consists of 3 styles in a range of Light-Moderate to Moderate-Heavy absorbencies, making them ideal to absorb your period and sweat, and keep you fresh and dry, way beyond the final whistle.

The PUMA x Modibodi collection is available online at modibodi.com.

The PUMA x Modibodi collection is available in selected stores and online at puma.com and modibodi.com.

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

MODIBODI

Since 2013, Modibodi® has had one goal – to make changing the world as easy as changing your underwear. What they didn’t realise, is that in doing so, they’d change the lives of their customers along the way.

Life-changing is the number one phrase heard from Modibodi customers. It’s a language woven into the brand’s DNA and sits firmly at the heart of what they do. Having made a name for itself globally, designing confidence-shaping, confidence-creating, planet-sustaining, life-changing apparel, Modibodi® offers comfort from periods, pee and bodily leaks, and champions conversations and initiatives that allow people to live more comfortably in themselves.

Designed with compassion and offering a sustainable solution to disposable products, Modibodi uses proprietary innovation and patented technology to ensure each and every one of their designs is market leading, saving billions of single-use disposable hygiene products from ending up in landfill.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005712/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release

The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse

Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye